PubRank

Anneke Grobler

Author PubWeight™ 35.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010 10.90
2 Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011 5.31
3 Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008 3.40
4 Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 2011 1.15
5 Strengthening biostatistics resources in sub-Saharan Africa: research collaborations through U.S. partnerships. Stat Med 2011 1.06
6 Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav 2014 1.06
7 Women's perceptions of the benefits and risks of skin-lightening creams in two South African communities. J Cosmet Dermatol 2014 0.98
8 Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa: a longitudinal study. AIDS Behav 2011 0.97
9 Anaemia in acute HIV-1 subtype C infection. PLoS One 2008 0.96
10 Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther 2012 0.94
11 Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res 2010 0.91
12 HIV prevention in high-risk women in South Africa: condom use and the need for change. PLoS One 2012 0.91
13 Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa. Antivir Ther 2012 0.88
14 Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. AIDS 2012 0.88
15 Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses 2011 0.87
16 The preventive misconception: experiences from CAPRISA 004. AIDS Behav 2014 0.86
17 The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J 2010 0.85
18 Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials 2014 0.83
19 The spectrum of skin diseases in a black population in Durban, KwaZulu-Natal, South Africa. Int J Dermatol 2014 0.82
20 An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clin Trials 2012 0.77